Abstract
We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
Volume: 14 Issue: 4
Author(s): Giulia Donvito, Isabella Bettoni, Francesca Comelli, Anita Colombo and Barbara Costa
Affiliation:
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
Abstract: We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Export Options
About this article
Cite this article as:
Donvito Giulia, Bettoni Isabella, Comelli Francesca, Colombo Anita and Costa Barbara, Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429111537
DOI https://dx.doi.org/10.2174/1871527314666150429111537 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Current HIV Treatment Guidelines - An Overview
Current Pharmaceutical Design Current Therapies and Emerging Targets for the Treatment of Diabetes
Current Pharmaceutical Design Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets A Promising Future for Peptides in Ophthalmology: Work Effectively and Smartly
Current Medicinal Chemistry Computer Aided Systems for Diabetic Retinopathy Detection Using Digital Fundus Images: A Survey
Current Medical Imaging Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders
Current Protein & Peptide Science Modeling and Informatics in Designing Anti-Diabetic Agents
Current Pharmaceutical Design Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets UKPDS Risk Engine, Decode and Diabetes PHD Models for the Estimation of Cardiovascular Risk in Patients with Diabetes
Current Diabetes Reviews Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders Nrf2 and NF-κB Modulation by Sulforaphane Counteracts Multiple Manifestations of Diabetic Neuropathy in Rats and High Glucose-Induced Changes
Current Neurovascular Research